Literature DB >> 8818742

The incidence of asymptomatic paroxysmal atrial fibrillation in patients treated with propranolol or propafenone.

R Wolk1, P Kulakowski, S Karczmarewicz, G Karpinski, E Makowska, A Czepiel, L Ceremuzynski.   

Abstract

Anti-arrhythmic therapy for paroxysmal atrial fibrillation leads to complete symptomatic relief in a number of patients. The elimination of symptoms may be associated either with a complete elimination of arrhythmia or with a conversion of symptomatic atrial fibrillation into asymptomatic episodes of arrhythmia. The aim of the study was to evaluate the occurrence of asymptomatic paroxysmal atrial fibrillation in 52 patients treated with propafenone (35 drug trials) or propranolol (34 drug trials) by means of ambulatory ECG Holter monitoring. Propafenone was clinically effective (complete relief of symptoms) in 26 (74%) patients. However, in 7 cases (27%) asymptomatic episodes of arrhythmia were still recorded when awake. In patients treated with propranolol clinical symptoms were absent in 18 (53%). However, in 4 (22%) patients attacks of paroxysmal atrial fibrillation were present. The mechanism of drug-induced conversion of symptomatic episodes of atrial fibrillation into asymptomatic spells of arrhythmia was a marked shortening in duration of episodes in 7 patients (from 2215 +/- 3843 s to 16 +/- 10 s, N.S.) or by a significant slowing of ventricular response during atrial fibrillation in 4 patients (from 125 +/- 27 to 84 +/- 8 beats/min, P = 0.05). In conclusion, in a significant proportion of patients with symptomatic paroxysmal atrial fibrillation asymptomatic episodes of arrhythmia may occur while on anti-arrhythmic drug therapy. Some of these patients, particularly those with other risk factors for stroke such as advanced age or the presence of organic heart disease, may require anti-coagulant therapy or change in anti-arrhythmic treatment, and can be selected on the basis of ambulatory ECG monitoring.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8818742     DOI: 10.1016/0167-5273(96)02631-9

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  8 in total

Review 1.  Clinical relevance of silent atrial fibrillation: prevalence, prognosis, quality of life, and management.

Authors:  I Savelieva; A J Camm
Journal:  J Interv Card Electrophysiol       Date:  2000-06       Impact factor: 1.900

Review 2.  Symptoms and functional status of patients with atrial fibrillation: state of the art and future research opportunities.

Authors:  Michiel Rienstra; Steven A Lubitz; Saagar Mahida; Jared W Magnani; João D Fontes; Moritz F Sinner; Isabelle C Van Gelder; Patrick T Ellinor; Emelia J Benjamin
Journal:  Circulation       Date:  2012-06-12       Impact factor: 29.690

3.  Effect of β-blockers on triggering of symptomatic atrial fibrillation by anger or stress.

Authors:  Rachel Lampert; Matthew M Burg; Larry D Jamner; James Dziura; Cynthia Brandt; Fangyong Li; Theresa Donovan; Robert Soufer
Journal:  Heart Rhythm       Date:  2019-06-03       Impact factor: 6.343

Review 4.  Atrial fibrillation and heart failure in the elderly.

Authors:  Pedram Kazemian; Gavin Oudit; Bodh I Jugdutt
Journal:  Heart Fail Rev       Date:  2012-09       Impact factor: 4.214

Review 5.  Current management of symptomatic atrial fibrillation.

Authors:  K S Channer
Journal:  Drugs       Date:  2001       Impact factor: 9.546

6.  An open label, randomised, crossover study comparing sotalol and atenolol in the treatment of symptomatic paroxysmal atrial fibrillation.

Authors:  R P Steeds; A S Birchall; M Smith; K S Channer
Journal:  Heart       Date:  1999-08       Impact factor: 5.994

7.  Electrophysiological characteristics associated with symptoms in pacemaker patients with paroxysmal atrial fibrillation.

Authors:  John Silberbauer; Rick A Veasey; Elizabeth Cheek; Nadeem Maddekar; Neil Sulke
Journal:  J Interv Card Electrophysiol       Date:  2009-07-28       Impact factor: 1.900

Review 8.  Long-term success and follow-up after atrial fibrillation ablation.

Authors:  S Kircher; G Hindricks; P Sommer
Journal:  Curr Cardiol Rev       Date:  2012-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.